{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 3,
  "pageCount": 58,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/3",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Development of More Innovative and Differentiated Therapies: Chinese pharmas have surely made some progresses in innovation in the past few years; however, many are concentrated around heated targets (such as PD-1, EGFR), leading to homogeneous competition. With companies starting to focus on new modalities, technology platforms and targets, more innovative and differentiated therapies are expected.\nIncreasing Focus of More Commercially Attractive Development Areas: Oncology has become the most heated TA for clinical development in China over the past few years. In the future, companies tend to consider more comprehensively when prioritizing drugs for R&D with commercial attractiveness being more of a key consideration. Other factors considered also include return on investment, company expertise, and feasibility to collaborate.\nAdoption of Smarter Clinical Trial Tools: As increasing complexity becomes the mega trend of clinical trial, demands for smart and digital tools are rising. Technologies such as EDC, CTMS, eTMF and PVS have already being widely adopted in China clinical trials. It is believed that smart and digital tools will be indispensable for future clinical trial, and revolutionary impact may even be witnessed.\nA Two-way Pursuit – Globalization of Chinese Biopharma & Evolution of MNC China R&D strategy: Globalization is increasingly an imperative for Chinese biopharmas and in order to succeed in oversea trial, careful prioritization of destination, oversea local team setup, and active communication with regulatory agencies are anticipated; With Chinese innovations being validated on the global stage, MNCs also tend to strengthen the cooperation with Chinese counterparts through license-in and incubation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "939b306b-5321-4a6a-adb9-f50a4ab9fa32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Though faced with challenges, the foundation for China healthcare market is still strong, which is expected to support the future high-quality growth of China clinical trial. Four strategic trends are anticipated as China clinical trial development pivoting to quality growth:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a369286-6c8d-4233-b53a-610a41d23731",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Executive summary: Future China clinical trials will pivot to high quality growth under four main strategic trends",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90101306-edc3-4ab2-bf1c-600d74fca075",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "3cea0ef1-d153-49fc-9265-df97b06090fa",
      "evidence": "Executive summary of future strategic trends",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "d4acf7a6-2c83-4ad1-87b2-d5cc913d92fe",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Situation & Context",
      "beatSlug": "consultants-gambit-situation-context",
      "evidence": "The report provides an overview of the clinical trials landscape in China, including key economic and healthcare indexes.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}